首页 | 官方网站   微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   5763篇
  免费   457篇
  国内免费   115篇
医药卫生   6335篇
  2021年   72篇
  2020年   45篇
  2019年   75篇
  2018年   88篇
  2017年   52篇
  2016年   80篇
  2015年   83篇
  2014年   110篇
  2013年   176篇
  2012年   255篇
  2011年   247篇
  2010年   171篇
  2009年   183篇
  2008年   242篇
  2007年   258篇
  2006年   197篇
  2005年   243篇
  2004年   178篇
  2003年   177篇
  2002年   212篇
  2001年   155篇
  2000年   184篇
  1999年   145篇
  1998年   139篇
  1997年   134篇
  1996年   143篇
  1995年   100篇
  1994年   91篇
  1993年   98篇
  1992年   115篇
  1991年   118篇
  1990年   126篇
  1989年   123篇
  1988年   122篇
  1987年   122篇
  1986年   121篇
  1985年   120篇
  1984年   78篇
  1983年   69篇
  1982年   67篇
  1981年   55篇
  1980年   61篇
  1979年   62篇
  1978年   57篇
  1977年   47篇
  1976年   56篇
  1975年   37篇
  1974年   41篇
  1970年   44篇
  1968年   41篇
排序方式: 共有6335条查询结果,搜索用时 15 毫秒
1.
Now is an exciting era of development in immunotherapy checkpoint inhibitors and their effect on the treatment of NPC. While the general prognosis of R/M disease is poor, immunotherapy offers some promise in a malignancy associated with EBV and characterized by a peritumoural immune infiltrate. Our study aims to review past and on-going clinical trials of monoclonal antibody therapies against the checkpoint inhibitors (e.g. PD1 and CTLA-4), in R/M NPC. All randomized and nonrandomized controlled trials involving immune checkpoint inhibitor interventions for treatment of NPC were included in the study. We utilized a validated “risk of bias” tool to assess study quality. Four separate Phase I–II trials report the potential of PD1 inhibitor treatment for patients with NPC. Within the observed groups, camrelizumab combined with chemotherapy achieved an objective response in 91% of patients as first-line treatment for metastatic NPC (PFS 68% at 1-year) but this was associated with a high rate of grade >3 adverse events (87%; CTCAE version 4.03). The remaining three studies focused on recurrent NPC disease in patients who had received at least one line of prior chemotherapy. Within this group, camrelizumab monotherapy achieved an objective response in 34% of patients (PFS 27% at 1-year; range across all three studies 20.5–34%). No NPC trial has yet reported on specific outcomes for non-PD1 checkpoint inhibitors but 11 on-going studies include alternative targets (e.g. PD-L1/CTLA-4) as combination or monotherapy treatments. In considering checkpoint immunotherapies for NPC, initial results show promise for anti-PD1 interventions. Further phase I–III trials are in progress to clarify clinical outcomes, fully determine safety profiles, and optimize drug combinations and administration schedules.  相似文献   
2.
ABSTRACT

Measuring hope reliably and accurately remains an important research objective, not least in less prosperous settings where ‘holding on to hope’ may be critically important in the struggle against adverse life conditions. The State Hope Scale was designed for use in the US. Despite reported application in diverse cultures and using translations the scale has not been extensively validated outside US populations. This study contributes to a larger project exploring the measurement of hope and provides a critique of Snyder’s scale as used in a Tanzanian female population of 1021 urban microfinance participants. We evaluate the scale’s validity through assessment of the empirical distribution of scores, item response profiles, internal consistency and discriminatory ability. Participants mostly scored very high and many reached very near the maximum attainable score. Hardly any endorsed the negative half of the response scale. Several problems are discussed including poor discrimination and strong evidence of acquiescence response bias. We also found little association of the scale scores with hypothesised correlates of hope. Future improvements on the measurement of hope are recommended, especially in studies outside the narrow Western context in which the scale was devised.  相似文献   
3.
颈动脉内膜切除术的恰当应用   总被引:2,自引:0,他引:2  
在颈动脉内膜切除术(CEA)首创的头30年里,一直没有明确的标准来确定哪些颈内动脉疾病患者适合这一手术.最近,从7项临床随机试验中得出了哪些有症状与无症状患者适合行CEA的结论.对于颈内动脉狭窄70%以上的患者,卒中的危险性最大,手术的益处也最大.在这些研究中,CEA对以下患者最有益半球短暂性脑缺血发作、颅内外联合病灶和无侧支循环且除此之外身体状况良好的老年患者.下列患者虽然能从手术中获益,但围手术期卒中和死亡的危险性较高广泛白质疏松、对侧颈内动脉闭塞和腔内有血栓者.狭窄50%~69%的患者较少获益,包括女性和仅有一过性单眼盲在内的一些患者行CEA甚至可能有害.腔隙性卒中和一侧颈内动脉接近闭塞的患者有手术指征,但益处不大;狭窄<50%的患者不能从手术中获益.在最大的一项无症状患者随机试验中,围手术期卒中和死亡的危险性非常小(1.5%),但要在2年内防止1例卒中发生需要相当多的病例(83例)接受CEA治疗.以后的文献报道围手术期危险性较高(2.8%~5.6%).近一半无症状患者的卒中是心源性栓塞和小血管疾病所致.这些局限性抵消了任何潜在的益处.其他试验正在进行,并可能确认哪些无症状患者亚组可从手术中获益.同时,大多数无症状患者内科治疗效果也较好.  相似文献   
4.
5.
6.
The present study evaluated the use of psychologic measures, in particular, the relatively new Million Behavioral Health Inventory (MBHI), in predicting change in physical function of chronic low back pain patients undergoing a functional restoration program. The first 134 consecutive patients completing this program were assessed. Results demonstrated that various clinical scales of the MBHI were predictive of improvement in physical function. In addition, various scales enabled discrimination between patients who completed the program and those who prematurely dropped out. Although this inventory shows promise in helping to predict response to treatment, no single psychologic test can reliably be used as the sole predictor in clinical cases.  相似文献   
7.
8.
This article is designed to help dentists make better decisions regarding capitation programs. It focuses on approaches to costs that can be useful. An example is given that illustrates how these cost concepts might be used to analyze a capitation proposal.  相似文献   
9.
Summary— To investigate if the functional alterations observed in resistance arteries of spontaneously hypertensive rats (SHRs) were also present at the coronary level, in vitro experiments were performed in mesenteric resistance arteries (MRA) and in right (RIC) and left interventricular coronary (LIC) arteries taken from 15–25-week-old SHR and age-matched Wistar Kyoto rats WKYs. Using a passive extension protocol, internal diameters corresponding to 100 mmHg intraluminal pressure (D100) were determined and vessels were set up to a normalized internal diameter (0.9 D100). SHR mesenteric resistance arteries had a significantly smaller diameter compared to WKY arteries, whereas both types of SHR coronary arteries had a greater diameter compared to those of WKY rats. In arteries in the absence of contracting agonist, nitro-L-arginine (NOLA, 100 μM) induced a progressive rise in basal tone, which could be reversed by subsequent addition of L-arginine (100 μM) but not D-arginine (100 μM). When expressed as percent of maximal contractions induced by agonists (noradrenaline, NA [10 μM] in MRA; serotonin, 5-HT [10 μM], in RIC and LIC), these contractions were significantly stronger in WKY compared to SHR coronary and mesenteric resistance arteries. In NA-precontracted MRA and 5HT-precontracted coronary arteries in the presence of indomethacin (10 μM), the magnitude of acetylcholine-induced maximal relaxations (expressed as percent of maximal contractions induced by agonists) was greater in WKY compared to SHR arteries. After a 30-min incubation period, NOLA (100 μM) completely inhibited relaxations induced by acetylcholine (0.01–10 μM) in all types of precontracted arteries. Subsequent additions of sodium nitroprusside, (SNP, 10 μM) induced complete relaxations in all preparations. These results show that a basal release of NO or NO-like compound by endothelial cells is present in isolated mesenteric resistance and coronary arteries of WKY rats and SHRs. The contribution of endothelium-derived relaxing factor-nitric oxide (EDRF-NO) to arterial tone was lower in MRA compared to coronary arteries in both strains and in SHR compared to WKY arteries. In the SHR preparations, the impaired relaxation induced by acetylcholine appeared to be due to a functional alteration of the endothelium in the presence of normal reactivity of the smooth muscle cells.  相似文献   
10.
麦冬类中药组织切片计算机三维重建图鉴   总被引:9,自引:0,他引:9  
利用计算机技术实现麦冬类中药组织连续切片三维重建与动态显示,为计算机辅助生药学鉴定和教学提供了新的三维图像技术和研究资料。  相似文献   
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司    京ICP备09084417号-23

京公网安备 11010802026262号